Richard C. Breeden - Feb 15, 2023 Form 4 Insider Report for STERIS plc (STE)

Role: Director
Signature: /s/ Ronald E. Snyder, Authorized Representative under Power of Attorney
Stock symbol: STE
Transactions as of: Feb 15, 2023
Transactions value $: $204,535
Form type: 4
Date filed: 2/17/2023, 03:35 PM
Previous filing: Aug 5, 2022
Next filing: May 16, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	STE	Ordinary Shares	Options Exercise	$205K	+4.66K	+12.2%	$43.92	42.8K	Feb 15, 2023	Direct
holding	STE	Ordinary Shares						27.2K	Feb 15, 2023	See Footnotes Below	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	STE	Director Stock Option (right to buy)	Options Exercise		-4.66K	-100%		0	Feb 15, 2023	Ordinary Shares	4.66K	$43.92	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Richard C. Breeden is the managing member of Breeden Capital Partners LLC, and managing member and chairman and chief executive officer of Breeden Capital Management LLC. Breeden Capital Partners LLC (the "General Partner") is in turn the general partner of Breeden Partners L.P. (the "Fund").
F2	Pursuant to Rule 16a-1(a)(2)(ii)(B) of the Securities Exchange Act of 1934, as amended, Mr. Breeden in his capacity as managing member, as well as chairman and chief executive officer of Breeden Capital Management LLC and as the managing member of Breeden Capital Partners LLC, may be deemed to be the indirect beneficial owner of the ordinary shares owned by the Fund and its General Partner, and may be deemed to have beneficial ownership of all such shares. Mr. Breeden disclaims beneficial ownership over 1,358 of these shares held by Breeden Partnership LLP.
F3	This option to purchase 4,657 STERIS plc ordinary shares, which is fully vested, was received in connection with the redomiciliation of STERIS plc to Ireland in March 2019 in exchange for an option to purchase 4,657 ordinary shares for $43.92 per share in STERIS plc prior to the redomiciliation ("Old STERIS"), subject to the same terms and conditions as the original Old STERIS stock option.